Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 9, 2010, Pages 2366-2378

  Saxena, Tanmai ^a   Lee, Eunjung ^a   Henderson, Katherine D ^b   Clarke, Christina A ^c,d   West, Dee ^c   Marshall, Sarah F ^e   Deapen, Dennis ^a   Bernstein, Leslie ^b   Ursin, Giske ^a,f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c NORTHERN CALIFORNIA CANCER CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BREAST BIOPSY; BREAST CANCER; CANCER RISK; CANCER SIZE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; ESTROGEN THERAPY; FAMILY HISTORY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MENARCHE; MENOPAUSAL SYNDROME; PARITY; PRIORITY JOURNAL; QUESTIONNAIRE; RACE; RISK FACTOR; SMOKING; TEACHER; TREATMENT DURATION; TUMOR; UNITED STATES;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CALIFORNIA; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; RISK FACTORS;

EID: 77956525878     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0162     Document Type: Article

References (48)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350: 1047-59.
2. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy. Int J Cancer 1999;81: 339-44.
3. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10:253-60. (Pubitemid 29358958)
4. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000;152:950-64.
5. Rockhill B, Colditz GA, Rosner B. Bias in breast cancer analyses due to error in age at menopause. Am J Epidemiol 2000;151:404-8. (Pubitemid 30463618)
6. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32. (Pubitemid 30117736)
7. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91. (Pubitemid 30648870)
8. Weiss LK, Burkman RT, Cushing-Haugen K, et al. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002; 100:1148-58. (Pubitemid 35449180)
9. Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003;97:1387-92. (Pubitemid 36297767)
10. Ursin G, Tseng CC, Paganini-Hill A, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 2002;20:699-706.
11. Colditz GA. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 2005;11:909-17s.
12. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-33.
13. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
14. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. JAMA 2004;291:47-53.
15. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the U.S. Food and Drug Administration. Am J Med 2005;118 Suppl 12B:64-73.
16. Hing E, Brett KM. Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003. Obstet Gynecol 2006; 108:33-40.
17. Coombs NJ, Cronin KA, Taylor RJ, Freedman AN, Boyages J. The impact of changes in hormone therapy on breast cancer incidence in the U.S. population. Cancer Causes Control 2010;21:83-90.
18. MacLennan AH, Gill TK, Broadbent JL, Taylor AW. Continuing decline in hormone therapy use: population trends over 17 years. Climacteric 2009;12:122-30.
19. Verkooijen HM, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas 2009; 64:80-5.
20. Hausauer AK, Keegan TH, Chang ET, Glaser SL, Howe H, Clarke CA. Recent trends in breast cancer incidence in U.S. white women by county-level urban/rural and poverty status. BMC Med 2009;7:31.
21. Birkhauser MH, Reinecke I. Current trends in hormone replacement therapy: perceptions and usage. Climacteric 2008;11:192-200.
22. Daling JR, Malone KE, Doody DR, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal and other histologic types of breast carcinoma. Cancer 2002;95:2455-64.
23. Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 2004;109:721-7. (Pubitemid 38405620)
24. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27. (Pubitemid 36999703)
25. Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 2006;7:910-8.
26. Pike MC, Wu AH, Spicer DV, Lee S, Pearce CL. Estrogens, progestins, and risk of breast cancer. Ernst Schering Found Symp Proc 2007;1:127-50.
27. Brinton LA, Richesson D, Leitzmann MF, et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev 2008;17:3150-60.
28. Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 2008;167: 1407-15.
29. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004;101:1490-500.
30. Chen WY, Colditz GA. Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nat Clin Pract Oncol 2007;4:415-23.
31. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the socalled triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007;109:1721-8. (Pubitemid 46668532)
32. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008;52:108-18.
33. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology 2009;41:40-7.
34. Bernstein L, Allen M, Anton-Culver H, et al. High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 2002;13: 625-35. (Pubitemid 35001770)
35. Rothman K, Greenland S. Modern epidemiology. 2nd edition. Philadelphia: Lippincott Williams & Wilkins; 1998.
36. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-87.
37. Hosmer D, Lemeshow S, May S. Applied survival analysis: regression modeling of time to event data. 2nd edition. New Jersey: John Wiley & Sons, Inc.; 2008.
38. Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 2004;112:130-4. (Pubitemid 39249500)
39. Hofvind S, Moller B, Thoresen S, Ursin G. Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer 2006;118:3112-7.
40. Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 2005; 92:2049-58.
41. Warren MP. A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol 2004;190:1141-67.
42. Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:593-600. (Pubitemid 34760816)
43. Cleland WH, Mendelson CR, Simpson ER. Effects of aging and obesity on aromatase activity of human adipose cells. J Clin Endocrinol Metab 1985;60:174-7.
44. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-63.
45. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 2008; 113:1521-6.
46. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34. (Pubitemid 46698581)
47. Li CI, Malone KE, Porter PL, et al. Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev 2008;17:43-50.
48. Li CI, Daling JR, Malone KE, et al. Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:946-54.